Ali Aminian, MD, FACS, FASMBS
WASHINGTON—In patients with obesity who also have type 2 diabetes and chronic kidney disease, surgery is a better renoprotective option than glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to findings presented at the 2024 annual meeting of the American Surgical Association.
“The fact is that nobody likes surgery, so if there’s a less invasive option available, people will tend to prefer it,” said lead